EPIM
CRSP icon

Evelyn Partners Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Evelyn Partners Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.8K Hold
1,300
– – ﹤0.01% 268
2025
Q4 		$68.2K Hold
1,300
– – ﹤0.01% 267
2025
Q3 		$84.3K Hold
1,300
– – ﹤0.01% 254
2025
Q2 		$63.2K Hold
1,300
– – ﹤0.01% 270
2025
Q1 		$44.2K Hold
1,300
– – ﹤0.01% 284
2024
Q4 		$51.2K Buy
+1,300
New +$61.4K ﹤0.01% 274

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Evelyn Partners Investment Management's CRSP Position: Q1 2026 in Review

Evelyn Partners Investment Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 1,300 shares worth $61.8K. The position accounts for ﹤0.01% of the portfolio, ranked #268.

Evelyn Partners Investment Management first reported a position in CRSP in Q4 2024 and has held it in 6 quarters since. The position peaked at $84.3K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Evelyn Partners Investment Management held 1,300 shares of CRISPR Therapeutics worth $61.8K as of Q1 2026.
  • Evelyn Partners Investment Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Evelyn Partners Investment Management's portfolio in Q1 2026, its #268 holding.
  • Evelyn Partners Investment Management first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Evelyn Partners Investment Management's CRISPR Therapeutics position peaked at $84.3K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Evelyn Partners Investment Management's 13F filing for Q1 2026, filed 15 May 2026.